Insider Selling: Omada Health (NASDAQ:OMDA) CEO Sells $264,057.60 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $20.40, for a total value of $264,057.60. Following the sale, the chief executive officer owned 411,861 shares of the company’s stock, valued at approximately $8,401,964.40. This represents a 3.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Omada Health Price Performance

Shares of OMDA stock opened at $23.67 on Friday. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92. The stock’s fifty day moving average price is $20.36 and its 200 day moving average price is $16.20. The company has a market cap of $1.41 billion, a price-to-earnings ratio of 473.40 and a beta of 1.73.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.10. The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. As a group, equities research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Omada Health from a “hold” rating to a “buy” rating in a research note on Saturday. Citigroup reissued an “outperform” rating on shares of Omada Health in a research report on Monday, July 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Omada Health in a research report on Friday, May 8th. Barclays lifted their price target on Omada Health from $20.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.25.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Omada reported revenue of approximately $87.8 million, above the $80.9 million consensus estimate. Adjusted earnings per share also surpassed forecasts, with reports citing approximately $0.08 to $0.15 per share versus expectations ranging from a loss of $0.02 to $0.05. Results improved from a year-earlier loss. Omada Health quarterly earnings report
• Positive Sentiment: Growth remained strong: Second-quarter revenue rose 43% year over year, while total members increased 45%. Omada also achieved a record quarterly gross margin, supporting the case that operating leverage and scale are improving. Omada Health second-quarter results
• Positive Sentiment: 2026 revenue guidance was raised or reaffirmed above consensus: Omada projected full-year revenue of $334 million to $340 million, exceeding the approximately $327.2 million analyst estimate. The outlook signals continued demand for its virtual chronic-care platform. Omada Health revenue outlook
• Neutral Sentiment: Leadership transition announced: Co-founder and CEO Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao is scheduled to become CEO. The planned, internal succession may provide continuity, although investors could monitor execution under the new leadership. Omada Health CEO transition
• Negative Sentiment: CEO stock sale adds a modest overhang: Duffy sold 12,944 shares for approximately $264,000, reducing his direct position by 3.05%. The sale occurred before the earnings release and may be routine, but insider selling can temper sentiment.

Institutional Trading of Omada Health

Several large investors have recently made changes to their positions in OMDA. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Omada Health during the fourth quarter valued at $1,222,000. a16z Perennial Management L.P. purchased a new stake in Omada Health in the fourth quarter valued at $2,480,000. Madryn Asset Management LP acquired a new stake in Omada Health during the 4th quarter worth about $9,212,000. Parallel Advisors LLC raised its stake in shares of Omada Health by 12,235.9% during the 4th quarter. Parallel Advisors LLC now owns 123,359 shares of the company’s stock valued at $1,947,000 after buying an additional 122,359 shares during the last quarter. Finally, Walleye Capital LLC raised its stake in shares of Omada Health by 677.2% during the 1st quarter. Walleye Capital LLC now owns 352,443 shares of the company’s stock valued at $4,430,000 after buying an additional 307,097 shares during the last quarter.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.